Preliminary study on patients located at the Kashani/Isfahan Hospital with multiple sclerosis between the years 2011 and 2013


1 Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Neurosciences Research Center; Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran

3 Department of Clinical Biochemistry, Isfahan University of Medical Sciences, Isfahan, Iran


Background: Multiple sclerosis (MS) is a multifactorial disease that could result from demyelination of the myelin sheath. The aim of this study is to investigate the demographic features and  rank the immunomodulating drugs in patients with MS.
Materials and Methods: This study was conducted in the MS clinic of the Isfahan Kashani Hospital, from 22 May, 2011 to 18 March, 2013. The data analyses (n = 1067) were divided  into two periods: (1) 2011/05/22 to 2012/03/18 denoted as P1 and (2) 2012/04/02 to 2013/03/18 denoted as P2.
 Most of drugs prescribed within the population studied were: Avonex, Betaferone, and Rebif. There was an increase in the number of female (n = 811) and male subjects (n = 256). During P1/P2 there was an increase from 460 to 607 in the total number of patients, respectively. The number of patients who attended the MS clinic once was 250 (P1) versus 430 (P2), and those more than four times was 71 (P1) versus 59 (P2) correspondingly.
Conclusion: The number of females increased from 2011 to 2013. Because of dissimilar ingredients additive of different pharmaceutical companies, it could be suggested that pharmacotherapy strategies, especially in Iranian population of MS with first-line treatment using Avonex, Betaferone and Rebif, more spotlighted on inter- and intra-individual variability based on clinical pharmacokinetics parameters


Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care 2013;19(Suppl 2):S15-20.  Back to cited text no. 1
Evans C, Beland SG, Kulaga S, Wolfson C, Kingwell E, Marriott J, et al. Incidence and prevalence of multiple sclerosis in the Americas: A systematic review. Neuroepidemiology 2013;40:195-210.  Back to cited text no. 2
Tennant A. Epidemiology of neurologically disabling disorders. Handb Clin Neurol 2013;110:77-92.  Back to cited text no. 3
Etemadifar M, Abtahi SH. Multiple sclerosis in Isfahan, Iran: Past, present and future. Int J Prev Med 2012;3:301-2.  Back to cited text no. 4
[PUBMED]  Medknow Journal  
Najafi MR, Shaygannajad V, Mirpourian M, Gholamrezaei A. Vitamin B (12) deficiency and multiple sclerosis; is there any association? Int J Prev Med 2012;3:286-9.  Back to cited text no. 5
[PUBMED]  Medknow Journal  
Etemadifar M, Janghorbani M, Shaygannejad V, Ashtari F. Prevalence of multiple sclerosis in Isfahan, Iran. Neuroepidemiology 2006;27:39-44.  Back to cited text no. 6
Etemadifar M, Maghzi AH. Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran. Mult Scler 2011;17:1022-7.  Back to cited text no. 7
Oreja-Guevara C, González-Segura D, Vila C. Spasticity in multiple sclerosis: Results of a patient survey. Int J Neurosci 2013;123:400-8.  Back to cited text no. 8
Antoniol C, Jilek S, Schluep M, Mercier N, Canales M, Le Goff G, et al. Impairment of JCV-specific T-cell response by corticotherapy: Effect on PML-IRIS management? Neurology 2012;79:2258-64.  Back to cited text no. 9
Annovazzi P, Tomassini V, Bodini B, Boffa L, Calabrese M, Cocco E, et al. A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. Neurol Sci 2013;34:197-203.  Back to cited text no. 10
Kalincik T, Horakova D, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, et al. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. Clin Neurol Neurosurg 2012;114:940-6.  Back to cited text no. 11
Anlar O. Treatment of multiple sclerosis. CNS Neurol Disord Drug Targets 2009;8:167-74.  Back to cited text no. 12
Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2012;12:CD006921.  Back to cited text no. 13
Arnason BG, Berkovich R, Catania A, Lisak RP, Zaidi M. Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler 2012;19:130-6.  Back to cited text no. 14
Tolou-Ghamari Z, Shaygannejad V, Ashtari F. Preliminary study related to the incidence of methylprednisolone pulse therapy in patients visited multiple sclerosis clinic located at the Isfahan Kashani Hospital. Int J Prev Med 2013;4(Suppl 2):S274-8.  Back to cited text no. 15
Acar M, Gedizlioglu M, Koskderelioglu A, Ozturk F, Kilinc S, Talay N. Effect of high-dose intravenous methyl-prednisolone treatment on intraocular pressure in multiple sclerosis patients with relapse. Eur Neurol 2012;68:20-2.  Back to cited text no. 16